Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Oxidative stress is produced by imbalance between reactive oxygen species and antioxidant
systems. This state is frequently associated with chronic diseases like obesity, insulin
resistance, metabolic syndrome and hepatic steatosis. In the liver, the oxidative stress may
trigger the progression of fatty liver disease, from triglyceride accumulation to
inflammation, cirrhosis and hepatocellular carcinoma. Thus, the attenuation of oxidative
stress, could be an important therapeutic target to lessen the severity of the disease. Until
now, there is not a medical treatment to cure non-alcoholic fatty liver disease, but
therapies aimed at reducing oxidative stress have been proposed. Metadoxine, an ionic complex
of pyridoxine-pyrrolidone molecule, acts as a synthetic antioxidant, forming traps that can
reduce free radicals; likewise, metadoxine has a proven capacity to reduce fat liver in
alcoholic hepatitis. Finally, in fact that alcoholic and non-alcoholic liver diseases share
molecular mechanisms in the generation of oxidative stress, the investigators propose
metadoxine as a posssible modifier of the oxidative stress in non-alcoholic liver disease,
prediabetic patients.
Phase:
Phase 4
Details
Lead Sponsor:
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran